Core Viewpoint - The Ardent Health class action lawsuit alleges that the company and its executives made misleading statements regarding financial practices and liability reserves, leading to significant stock price declines following revelations of financial mismanagement [3][4]. Group 1: Allegations and Financial Impact - The lawsuit claims that Ardent Health did not rely on accurate methods for determining the collectability of accounts receivable, which inflated reported financial positions [3]. - On November 12, 2025, Ardent Health disclosed a $43 million decrease in third quarter 2025 revenue due to revised accounts receivable assessments, resulting in a nearly 34% drop in stock price [4]. - The company cut its 2025 EBITDA guidance by approximately 9.6%, from a range of $575 million - $615 million to $530 million - $555 million, citing persistent industry-wide cost pressures [4]. Group 2: Class Action Details - Investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, can seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [5]. - Robbins Geller Rudman & Dowd LLP, the firm handling the case, is recognized as a leading complex class action firm with a strong track record in securities fraud litigation [6].
INVESTOR NOTICE: Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ARDT